Q-omics provides the consensus-scored MIR200A profile across patient tissues and cancer cell-line models. MIR200A expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, MIR200A is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, MIR200A RNA expression shows 14,317 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, KIRC, and THYM as cancer lineages where MIR200A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR200A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR200A survival associations across molecular data types. MIR200A RNA expression shows survival associations in the most cancer types (20), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR200A RNA expression–survival associations across cancer types. High MIR200A expression shows unfavorable associations in CESC, DLBC, UCEC and KIRC, but favorable associations in HNSC and STAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify HNSC as the clearest survival context for MIR200A RNA expression.
This table summarizes MIR200A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR200A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR200A shows lower tumor expression in KIRC, KIRP and BRCA and higher tumor expression in COAD, STAD and CHOL. The KIRC box plot shows higher MIR200A RNA expression in normal versus tumor tissue (log2 FC = −0.591, t-test p < 0.001).
This table shows molecular features associated with MIR200A in patient tissues and cancer cell lines. In patient samples, MIR200A shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, MIR200A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC.
